LogicBio Therapeutics Inc
NASDAQ:LOGC 9:33:49 AM EDT
| Market Cap (Intraday) | 107.31M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $4.92 |
| 50-Day MA | $6.58 |
| 200-Day MA | $7.16 |
LogicBio Therapeutics Inc Stock, NASDAQ:LOGC
65 Hayden Avenue, 2nd floor, Lexington, Massachusetts 02421
United States of America
Phone: +1.617.245.0399
Number of Employees: 39
Description
LogicBio Therapeutics, Inc. engages in the development of genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline include LB-001, LB-301, LB-201, and LB-101. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.